Cutler Group LP Tempest Therapeutics, Inc. Put Options Transaction History
Cutler Group LP
- $307 Million
- Q1 2024
Put Options
1 transactions
Others Institutions Holding TPST
# of Institutions
39Shares Held
6.35MCall Options Held
34.9KPut Options Held
148K-
Versant Venture Management, LLC San Francisco, CA3.51MShares$3.3 Million4.35% of portfolio
-
Black Rock Inc. New York, NY550KShares$517,2260.0% of portfolio
-
Jane Street Group, LLC New York, NY493KShares$463,5080.0% of portfolio
-
Geode Capital Management, LLC Boston, MA354KShares$333,0190.0% of portfolio
-
Ubs Group Ag196KShares$183,9350.0% of portfolio
About Tempest Therapeutics, Inc.
- Ticker TPST
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 10,418,900
- Market Cap $9.79M
- Description
- Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxiso...